Bibliography
- Bernstein DI : Potential for immunotherapy in the treatment of herpesvirus infections.Herpes8, 8–11 (2001).
- Cunningham AL , MikloskaZ: The Holy Grail: immune control of human herpes simplex virus infection and disease.Herpes8(Suppl. 1), A6–A10 (2001).
- Pollara G , KatzDR, ChainBM: The host response to herpes simplex virus infection.Curr. Opin. Infect. Dis.17, 199–203 (2004).
- Toka FN , PackCD, RouseBT: Molecular adjuvants for mucosal immunity.Immunol. Rev.199, 100–112 (2004).
- Zimmerman DH , RosenthalKS: The L.E.A.P.S. approach to vaccine development.Front Biosci.10, 790–798 (2005).
- Stanberry LR , CunninghamAL, MindelAet al.: Prospects for control of herpes simplex virus disease through immunization.Clin. Infect. Dis.30, 549–566 (2000).
- Stanberry LR , SpruanceSL, CunninghamAL: Glycoprotein-D-adjuvant vaccine to prevent genital herpes.N. Engl. J. Med.347, 1652–1661 (2002).
- Stephenson J : Genital herpes vaccine shows limited promise.JAMA284, 1913–1914 (2000).
- Connor RI , KorberBT, GrahamBS: Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.J. Virol.72, 1552–1576 (1998).
- Tramont EC , JohnstonMI: Progress in the development of an HIV vaccine.Expert Opin. Emerg. Drugs8, 37–452 (2003).
- Zolla-Pazner S : Identifying epitopes of HIV-1 that induce protective antibodies.Nat. Rev. Immunol.4, 199–210 (2004).
- Skinner GR , FinkC, MellingJet al.: Report of twelve years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis.Med. Microbiol. Immunol. (Berl.)180, 305–320 (1992).
- Skinner GR , TurykME, BensonCAet al.: The efficacy and safety of Skinner herpes simplex vaccine towards modulation of herpes genitalis; report of a prospective double-blind placebo-controlled trial.Med. Microbiol. Immunol. (Berl.)186, 31–36 (1997).
- Boursnell ME , EntwisleC, BlakeleyDet al.: A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease.J. Infect. Dis.175, 16–25 (1997).
- Da Costa XJ , JonesCA, KnipeDM: Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection.Proc. Natl Acad. Sci. USA96, 6994–6998 (1999).
- Dudek T , KnipeDM: Replication-defective viruses as vaccines and vaccine vectors.Virology344, 230–239 (2006).
- Morrison LA , Da CostaXJ, KnipeDM: Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge.Virology243, 178–87 (1998).
- Wald A , CoreyL, ConeR, HobsonA, DavisG, ZehJ: Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment.J. Clin. Invest.99, 1092–1097 (1997).
- Wald A , ZehJ, SelkeSet al.: Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.N. Engl. J. Med.342, 844–850 (2000).
- Buddingh GJ , SchrumDI, LanierJC, GuidryDJ: Studies of the natural history of herpes simplex virus infections.Pediatrics11, 593–605 (1953).
- Kinghorn GR : Epidemiology of genital herpes.J. Int. Med. Res.22, A14–A23 (1994).
- Scott DA , CoulterWA, LameyPJ: Oral shedding of herpes simplex virus type 1: a review.J. Oral Pathol. Med.26, 441–447 (1997).
- Halford WP , WeisendC, GraceJet al.: ICP0 antagonizes Stat 1-dependent repression of herpes simplex virus: implications for the regulation of viral latency.Virol. J.3, 44 (2006).
- Harle P , SainzBJr, CarrDJ, HalfordWP: The immediate-early protein, ICP0, is essential for the resistance of herpes simplex virus to interferon-α/β.Virology293, 295–304 (2002).
- Leib DA , HarrisonTE, LasloKM, MachalekMA, MoormanNJ, VirginHW: Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo.J. Exp. Med.189, 663–672 (1999).
- Leib DA , MachalekMA, WilliamsBR, SilvermanRH, VirginHW: Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene.Proc. Natl Acad. Sci. USA97, 6097–6101 (2000).
- Mossman KL , SaffranHA, SmileyJR: Herpes simplex virus ICP0 mutants are hypersensitive to interferon.J. Virol.74, 2052–2056 (2000).
- Mossman KL , SmileyJR: Herpes simplex virus ICP0 and ICP34.5 counteract distinct interferon-induced barriers to virus replication.J. Virol.76, 1995–1998 (2002).
- Lubinski JM , WangL, SoulikaAMet al.: Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo.J. Virol.72, 8257–8263 (1998).
- Nagashunmugam T , LubinskiJ, WangLet al.: In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor.J. Virol.72, 5351–5359 (1998).
- Hill A , JugovicP, YorkI: Herpes simplex virus turns off the TAP to evade host immunity.Nature375, 411–415 (1995).
- York IA , RoopC, AndrewsDW, RiddellSR, GrahamFL, JohnsonDC: A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes.Cell77, 525–535 (1994).
- Khanna KM , LepistoAJ, HendricksRL: Immunity to latent viral infection: many skirmishes but few fatalities.Trends Immunol.25, 230–234 (2004).
- Koelle DM , CoreyL: Recent progress in herpes simplex virus immunobiology and vaccine research.Clin. Microbiol. Rev.16, 96–113 (2003).
- Morrison LA : Vaccines against genital herpes: progress and limitations.Drugs62, 1119–1129 (2002).
- Whitley RJ , RoizmanB: Herpes simplex viruses: is a vaccine tenable?J. Clin. Invest.110, 145–151 (2002).
- Bolovan CA , SawtellNM, ThompsonRL: ICP34.5 mutants of herpes simplex virus type 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures.J. Virol.68, 48–55 (1994).
- Davison AJ : Evolution of the herpesviruses.Vet. Microbiol.86, 69–88 (2002).
- Orr MT , EdelmannKH, VieiraJ, CoreyL, RauletDH, WilsonCB: Inhibition of MHC class I is a virulence factor in herpes simplex virus infection of mice.PLoS Pathog.1, E7 (2005).